GLI1 activation is a key mechanism of erlotinib resistance in human non-small cell lung cancer

Lung cancer is the leading cause of cancer-associated death worldwide. In recent years, the advancement of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) targeted therapies has provided clinical benefits for lung cancer patients with EGFR mutations. The response to EGFR-TKI va...

Descripción completa

Detalles Bibliográficos
Autores principales: Dong, Zhouhuan, Wang, Yun, Ding, Vivianne, Yan, Xiang, Lv, Yali, Zhong, Mei, Zhu, Fengwei, Zhao, Po, He, Charlotte, Ding, Feng, Shi, Huaiyin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2020
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7436900/
https://www.ncbi.nlm.nih.gov/pubmed/32863909
http://dx.doi.org/10.3892/ol.2020.11937

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7436900/
https://www.ncbi.nlm.nih.gov/pubmed/32863909
http://dx.doi.org/10.3892/ol.2020.11937

Ejemplares similares